Phase 3 Liver Cancer Trial, Recruiting NCT05744219 Sponsor: Jon Unosson Condition: Liver Cancer
Back to Liver Cancer

Phase 3 Liver Cancer Trial, Recruiting

NCT05744219
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to provide written consent to participate
  • Both men and women are eligible
  • People who weigh more than 50 kg
  • People who are 18 years of age or older
  • People who are scheduled to have a complex aortic surgery, liver removal surgery, or pancreatic removal surgery

Who may not be able to join:

  • People whose life expectancy is less than six months
  • People who have received iron through an intravenous (IV) drip within one month before their surgery
  • People with severely low iron levels in the blood before surgery (confirm with trial site)
  • People for whom the study drug, Ferric Carboxymaltose, is medically unsuitable based on its official product guidelines (confirm with trial site)
  • People who have a condition where the body stores too much iron, such as hemochromatosis
  • People where there is a risk that too little of the liver would remain after surgery (confirm with trial site)
  • People who are already receiving kidney dialysis or a similar kidney treatment before surgery
  • People who have taken part in another drug or medical device study in the 30 days before joining this trial
  • People who have another major surgery planned before the five-week follow-up appointment for this trial
  • People the trial investigator considers unsuitable for inclusion for any other reason
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +46186110000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Jon Unosson
Registry
ClinicalTrials.gov
Start date
4 September 2024
Est. completion
31 December 2027

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Recovery after iv Iron

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov